Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 0.49 |
| ▸ | PDE4A | P27815 | 4/20 | 0.43 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19241609 | 0.86 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL29895375 | 0.86 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL17570891 | 0.85 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL18872917 | 0.84 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5357632 | 0.81 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL16084622 | 0.80 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5356884 | 0.80 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL7361038 | 0.80 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL5357639 | 0.80 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DRORC | |
| SCHEMBL14577351 | 0.80 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4DRORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233373-A1 | Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | ELI LILLY AND COMPANY (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2016033776-A1 | CRYSTALLINE (2S) -3- [ (3S, 4S) -3- [ (1R) -1-HYDROXYETHYL] -4- (4-METHOXY-3- { [1- (5-METHYLPYRIDIN-2-YL) AZETIDIN-3-YL] OXY} PHENYL) -3-METHYLPYRROLIDIN-1-YL] -3-OXOPROPANE-1, 2-DIOL | ELI LILLY AND COMPANY (US) | 2016-03-10 | — | — | WO | disclosed |
| WO-2016036596-A1 | CRYSTALLINE (2S)-3-[(3S,4S)-3-[(1R)-1-HYDROXYETHYL]-4-(4-METHOXY-3-{[1-(5-METHYLPYRIDIN-2-YL)AZETIDIN-3-YL]OXY}PHENYL) -3-METHYLPYRROLIDIN-1-YL]-3-OXOPROPANE-1,2-DIOL | ELI LILLY AND COMPANY (US) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233373-A1 | Crystalline (2S)-3-[(3S,4S)-3-[(1R)-1-hydroxyethyl]-4-(4-methoxy-3-phenyl)-3-methylpyrrolidin-1-yl]-3-oxopropane-1,2-diol | ADRA1D, OPRD1, CHRM3 | PDE4B 69/4885PDE4A 63/4885PDE4C 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.